Seattle Based Immusoft News Today

Immusoft, a Seattle-based biotech company, has become the first to genetically engineer B cells and test them in a patient with a genetic disorder.

Takeda Pharmaceutical is partnering with startup Immusoft in a research alliance aiming to develop B cell therapies that cross the blood-brain barrier to treat rare neurometabolic disorders. Depending on the progress of the research, Takeda could pay its new partner more than $900 million.